By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm today said that the underwriters for its initial public offering have exercised their over-allotment option, purchasing an additional 833,750 shares of the firm's common stock for $13.50 per share.

Fluidigm went public last week, selling 5,558,333 shares of common stock at a price of $13.50 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.